NAIROBI – Neonatal sepsis is one of the leading causes of newborn deaths globally, and increasing pathogen resistance to available first-line treatments is a prime example of rising antimicrobial resistance. That is why the Global Antibiotic Research and Development Partnership (GARDP) – a non-profit research organisation that develops new or improved antibiotic treatments – is […] Continue reading ->
The Global Antibiotic Research & Development Partnership (GARDP) has announced its new “5 BY 25” strategy to mobilise global stakeholders to raise the €500 million needed to develop and deliver five new antibiotic treatments by 2025, to help tackle antimicrobial resistance (AMR). Drug-resistant infections already cause at least 700,000 deaths globally each year, and affect […] Continue reading ->
The World Health Organization (WHO) today launched a global AWaRe campaign, which aims to support national health systems to make more judicious use of lifesaving drugs so as to combat a worldwide trend of antimicrobial resistance (AMR) – including increased pathogen resistance to common antibiotics, antivirals and anti-fungal medications. However, WHO’s own 2018 Report on […] Continue reading ->
[GARDP Press Release] [Geneva/San Francisco/Brisbane/Saarbrücken – 11 April 2019]  Multi-actor partnership tests natural products and compound libraries for antibacterial activity Discovery efforts will focus on World Health Organization’s (WHO) priority pathogens  The Global Antibiotic Research and Development Partnership (GARDP) is partnering with Calibr, the Helmholtz Centre for Infection Research (HZI), in particular its location Helmholtz-Institute […] Continue reading ->